A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 13 Dec 2018 Planned End Date changed from 24 Jun 2021 to 7 Jan 2022.
- 13 Dec 2018 Planned initiation date changed from 5 Dec 2018 to 31 Jan 2019.
- 25 Oct 2018 New trial record